Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Crescent Biopharma (NASDAQ:CBIO) has appointed Jan Pinkas, Ph.D. as Chief Scientific Officer. Dr. Pinkas brings over 20 years of experience in oncology drug development, with expertise in antibody-drug conjugates (ADCs) and translational research.
The appointment comes at a crucial time as Crescent prepares to advance two key programs: CR-001, a PD-1 x VEGF bispecific antibody expected to begin Phase 1 trials in early 2026, and CR-002, a novel ADC with planned IND submission in mid-2026. Dr. Pinkas previously served as CSO at Pyxis Oncology and held senior positions at Magenta Therapeutics and ImmunoGen, where he contributed to the development of ELAHERE® for ovarian cancer and SARCLISA® for multiple myeloma.
Crescent Biopharma (NASDAQ:CBIO) ha nominato Jan Pinkas, Ph.D. come Chief Scientific Officer. Il dottor Pinkas vanta oltre 20 anni di esperienza nello sviluppo di farmaci oncologici, con competenze specifiche negli anticorpi coniugati a farmaci (ADC) e nella ricerca traslazionale.
La nomina avviene in un momento cruciale, mentre Crescent si prepara a portare avanti due programmi chiave: CR-001, un anticorpo bispecifico PD-1 x VEGF che dovrebbe iniziare le sperimentazioni di Fase 1 all'inizio del 2026, e CR-002, un nuovo ADC con la presentazione dell'IND prevista per metà 2026. Il dottor Pinkas ha precedentemente ricoperto il ruolo di CSO presso Pyxis Oncology e ha occupato posizioni senior presso Magenta Therapeutics e ImmunoGen, dove ha contribuito allo sviluppo di ELAHERE® per il cancro ovarico e SARCLISA® per il mieloma multiplo.
Crescent Biopharma (NASDAQ:CBIO) ha designado a Jan Pinkas, Ph.D. como Director Científico. El Dr. Pinkas aporta más de 20 años de experiencia en el desarrollo de fármacos oncológicos, con especialización en conjugados anticuerpo-fármaco (ADC) e investigación traslacional.
Este nombramiento llega en un momento clave, ya que Crescent se prepara para avanzar en dos programas importantes: CR-001, un anticuerpo bispecífico PD-1 x VEGF que se espera inicie ensayos de Fase 1 a principios de 2026, y CR-002, un ADC novedoso con la presentación del IND prevista para mediados de 2026. El Dr. Pinkas fue anteriormente CSO en Pyxis Oncology y ocupó cargos senior en Magenta Therapeutics e ImmunoGen, donde contribuyó al desarrollo de ELAHERE® para cáncer de ovario y SARCLISA® para mieloma múltiple.
Crescent Biopharma (NASDAQ:CBIO)는 Jan Pinkas 박사를 최고과학책임자(CSO)로 임명했습니다. Pinkas 박사는 항체-약물 접합체(ADC) 및 전임상 연구 분야에서 전문성을 갖춘 종양학 약물 개발 경력 20년 이상을 보유하고 있습니다.
이번 임명은 Crescent가 두 가지 주요 프로그램을 추진하는 중요한 시점에 이루어졌습니다: CR-001은 2026년 초에 1상 임상을 시작할 예정인 PD-1 x VEGF 이중특이성 항체이며, CR-002는 2026년 중반에 IND 제출을 계획 중인 신약 ADC입니다. Pinkas 박사는 이전에 Pyxis Oncology에서 CSO로 근무했으며, Magenta Therapeutics와 ImmunoGen에서 고위직을 맡아 난소암 치료제 ELAHERE®와 다발성 골수종 치료제 SARCLISA® 개발에 기여했습니다.
Crescent Biopharma (NASDAQ:CBIO) a nommé Jan Pinkas, Ph.D. au poste de Chief Scientific Officer. Le Dr Pinkas possède plus de 20 ans d'expérience dans le développement de médicaments en oncologie, avec une expertise en conjugués anticorps-médicament (ADC) et en recherche translationnelle.
Cette nomination intervient à un moment clé alors que Crescent s'apprête à faire avancer deux programmes majeurs : CR-001, un anticorps bispécifique PD-1 x VEGF dont le début des essais de phase 1 est prévu début 2026, et CR-002, un nouvel ADC avec une soumission IND prévue pour la mi-2026. Le Dr Pinkas a précédemment été CSO chez Pyxis Oncology et a occupé des postes de direction chez Magenta Therapeutics et ImmunoGen, où il a contribué au développement d'ELAHERE® pour le cancer de l'ovaire et de SARCLISA® pour le myélome multiple.
Crescent Biopharma (NASDAQ:CBIO) hat Jan Pinkas, Ph.D. zum Chief Scientific Officer ernannt. Dr. Pinkas bringt über 20 Jahre Erfahrung in der Onkologie-Arzneimittelentwicklung mit, spezialisiert auf Antikörper-Wirkstoff-Konjugate (ADCs) und translationale Forschung.
Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Crescent zwei wichtige Programme vorantreibt: CR-001, einen PD-1 x VEGF bispezifischen Antikörper, der Anfang 2026 in die Phase-1-Studien starten soll, und CR-002, ein neuartiges ADC mit geplanter IND-Einreichung Mitte 2026. Dr. Pinkas war zuvor CSO bei Pyxis Oncology und hatte leitende Positionen bei Magenta Therapeutics und ImmunoGen inne, wo er zur Entwicklung von ELAHERE® für Eierstockkrebs und SARCLISA® für multiples Myelom beitrug.
- Appointment of highly experienced CSO with over 20 years in oncology drug development
- Two promising drug candidates advancing towards clinical trials in 2026
- New CSO brings successful track record in developing FDA-approved cancer therapies
- Both lead drug candidates still in pre-clinical stage
- Clinical trials not starting until early 2026
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors
WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs).
“We are thrilled to welcome Jan to Crescent’s leadership team. His depth of experience developing oncology therapeutics will be instrumental in driving innovation across our portfolio to bring better treatments to patients with solid tumors,” said Joshua Brumm, chief executive officer of Crescent. “Jan joins us at an important time as we progress our first two programs towards the clinic. In early 2026, we expect to be dosing patients in a global Phase 1 trial of CR-001, our PD-1 x VEGF bispecific antibody, and anticipate an IND submission in the middle of next year for one of our novel ADCs, CR-002. The addition of Jan underscores Crescent’s commitment to become a leader in delivering the next wave of cancer therapies.”
“Our pipeline is designed to leverage the shift to cooperative PD-1 x VEGF and next generation ADCs, including opportunities as monotherapies and synergistic combinations of these programs. Crescent is positioned at the forefront of therapeutic advancements for oncology, and I’m excited to work with this talented team to rapidly develop therapies that have the potential to be life-changing for people with cancer,” said Dr. Pinkas.
Prior to joining Crescent, Dr. Pinkas was chief scientific officer at Pyxis Oncology, where he established the preclinical research and development function to support ADC and antibody programs through Investigational New Drug (IND)-enabling studies and led the translational medicine group. Previously, at Magenta Therapeutics, Dr. Pinkas served as senior vice president, translational sciences, establishing a new department to support programs as the company advanced from preclinical research to late-stage clinical development. Prior to Magenta, Dr. Pinkas worked at ImmunoGen for more than 10 years in positions of increasing responsibility, most recently as vice president, translational research and development. In that role, he led groups supporting molecules from early-stage research to IND, and also advancing to pivotal clinical development, including contributing to ELAHERE®, an ADC approved for the treatment of platinum-resistant ovarian cancer, as well as SARCLISA®, an anti-CD38 therapy approved in combination with standard of care for multiple myeloma. Earlier in his career, he held scientist roles focused on oncology research at Amgen and Genzyme Corporation.
Dr. Pinkas earned his Ph.D. in molecular and cellular biology at the University of Massachusetts, Amherst and received his B.A. in biology from Johns Hopkins University.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation: Crescent’s business strategy; Crescent’s ability to achieve the expected benefits or opportunities with respect to CR-001, CR-002 and CR-003, both as monotherapies and synergistic combinations; the expected timelines of regulatory filings for CR-001 and CR-002; the expected commencement of clinical trials for CR-001; the potential for Crescent to become a leader in delivering the next wave of therapies for cancer patients; and Crescent’s business plans and the anticipated benefits of management changes. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Crescent will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Crescent’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to those uncertainties and factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its registration statement on Form S-4, most recently amended on May 12, 2025 and declared effective by the SEC on May 14, 2025), as well as risk factors associated with companies, such as Crescent, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Crescent.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
FAQ
Who is the new Chief Scientific Officer of Crescent Biopharma (NASDAQ:CBIO)?
What are Crescent Biopharma's (CBIO) main drug candidates in development?
What is Dr. Pinkas's previous experience in drug development?
When will Crescent Biopharma (CBIO) begin clinical trials for CR-001?
What therapeutic areas does Crescent Biopharma (NASDAQ:CBIO) focus on?
